Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome

Clin Nephrol. 1988 Nov;30(5):276-81.

Abstract

To determine if a selective thromboxane (TX)A2 synthetase inhibitor is clinically effective for the treatment of nephrotic syndrome, 11 patients with nephrotic syndrome were treated only with OKY-046, (E)-3-4-(1-imidazolylmethyl)phenyl-2-propenoic acid hydrochloride monohydrate, for at least 8 weeks. Urinary excretion of protein, TXB2, 2,3-dinor-TXB2, and beta-N-acetyl-D-glucosaminidase decreased with OKY-046. Creatinine clearance value, and urinary excretion of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha), however, did not show any significant change, while serum albumin level increased. Two patients with minimal change nephrotic syndrome showed complete remission only with OKY-046. These results demonstrate that the selective TXA2 synthetase inhibitor is an effective drug for the treatment of chronic glomerulonephritis accompanied by nephrotic syndrome.

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / urine
  • Acrylates / therapeutic use*
  • Adolescent
  • Adult
  • Aged
  • Female
  • Glomerulonephritis / complications
  • Glomerulonephritis / drug therapy
  • Glomerulonephritis / urine
  • Humans
  • Male
  • Methacrylates / metabolism
  • Methacrylates / therapeutic use*
  • Middle Aged
  • Nephrosis, Lipoid / drug therapy
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / etiology
  • Nephrotic Syndrome / urine
  • Proteinuria / urine
  • Thromboxane B2 / analogs & derivatives
  • Thromboxane B2 / urine
  • Thromboxane-A Synthase / antagonists & inhibitors*

Substances

  • Acrylates
  • Methacrylates
  • Thromboxane B2
  • 6-Ketoprostaglandin F1 alpha
  • 2,3-dinor-thromboxane B2
  • Thromboxane-A Synthase
  • ozagrel